Non-in situ hybridization method for detecting chromosomal abnormalities

• US 20060292576A1
• Filed: 06/23/2005
• Published: 12/28/2006
• Est. Priority Date: 06/23/2005
• Status: Abandoned Application

• Current Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Original Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Inventors: Albitar, Maher, Chan, Huai-En Huang
• Application Number:
  US11/165,445
• Publication Number:
  US 20060292576A1
• Time in Patent Office: Days
• US Class Current: 435/6.16
• CPC Class Codes: C12Q 1/6834 Enzymatic or biochemical coupling of nucleic acids to a solid phase
• CPC Class Codes: C12Q 2537/125 Sandwich assay format
• CPC Class Codes: C12Q 2563/149 Particles, e.g. beads
• CPC Class Codes: C12Q 2565/626 being a flow cytometer

Abstract

The present invention provides methods of detecting chromosomal or genetic abnormalities associated with various diseases or with predisposition to various diseases. In particular, the present invention provides advanced methods of performing DNA hybridization, capture, and detection on solid support. Invention methods are useful for the detection, diagnosis, predicting response to therapy, detecting minimal residual disease, prognosis, or monitoring of disease treatment or progression of particular disease conditions such as cell proliferative disorders

Claims

1. A method for detecting a target nucleic acid in a test sample, said method comprising:

forming on a solid support a complex comprising the target nucleic acid, a first nucleic acid probe hybridizing to a first segment of the target nucleic acid, said first nucleic acid probe labeled with a detectable label, and a second nucleic acid probe hybridizing to a second segment of the target nucleic acid, said second nucleic acid probe anchored to the solid support, and detecting said complex by detecting incorporated detectable label, wherein at least one of said first and second nucleic probe is at least 50 nucleotides in length.

2. The method of claim 1, wherein said solid support comprises a first member of a binding pair and said second probe comprises a second member of a binding pair which has binding affinity for said first member of a binding pair, and wherein binding of the first member of the binding pair to the second member of the binding pair anchors the second probe to the support.

3. The method of claim 2, wherein said complex is formed by hybridizing said target nucleic acid to said first nucleic acid probe and to said second nucleic acid probe prior to contacting the complex with said solid support comprising a first member of a binding pair.

4. The method of claim 1, wherein said solid support is one or more beads or one or more microwell plates.

5. The method of claim 2, wherein said binding pair is selected from the group consisting of ligand-receptor, a hormone-receptor, an oligonucleotide-complement, and antigen-antibody.

6. The method of claim 5, wherein said ligand-receptor is biotin and streptavidin or avidin.

7. The method of claim 1, wherein said nucleic acid probes are selected from the group consisting of oligonucleotide probes, artificial chromosome probes, fragmented artificial chromosome probes, genomic DNA probes, RNA probes, and recombinant nucleic acid probes.

8. The method of claim 1, wherein the first nucleic acid probe is labeled with a fluorophore.

9. The method of claim 1, wherein said complex is detected on the solid support by flow cytometry.

10. The method of claim 1, wherein said complex is detected by detecting a labeled reagent that binds to the detectable label of the first nucleic acid probe.

11. The method of claim 10, wherein said labeled reagent is a labeled antibody that is specific for the detectable label.

12. A method for detecting the presence or absence of a genetic abnormality in a target nucleic acid in a test sample, said method comprising:

forming on a solid support a complex comprising the target nucleic acid, a first nucleic acid probe hybridizing to a first segment of the target nucleic acid, said first nucleic acid probe labeled with a detectable label, and a second nucleic acid probe hybridizing to a second segment of the target nucleic acid, said second nucleic acid probe anchored to the solid support, and detecting said complex by detecting incorporated detectable label, wherein hybridization of both the first and second probes to the same target nucleic acid indicates detection of genetic abnormality in the target nucleic acid, while hybridization of only one of said probes to the same target nucleic acid indicates the absence of a genetic abnormality in the target nucleic acid.

13. The method of claim 12, wherein said solid support comprises a first member of a binding pair and said second probe comprises a second member of a binding pair which has binding affinity for said first member of a binding pair, and wherein binding of the first member of the binding pair to the second member of the binding pair anchors the second probe to the support.

14. The method of claim 13, wherein said complex is formed by hybridizing said target nucleic acid to said first nucleic acid probe and to said second nucleic acid probe prior to contacting the complex with said solid support.

15. The method of claim 12, wherein said solid support is one or more beads or one or more microwell plates.

16. The method of claim 13, wherein said binding pair is selected from the group consisting of ligand-receptor, a hormone-receptor, an oligonucleotide-complement, and antigen-antibody.

17. The method of claim 16, wherein said ligand-receptor is biotin and streptavidin or avidin.

18. The method of claim 12, wherein said nucleic acid probes are selected from the group consisting of oligonucleotide probes, artificial chromosome probes, fragmented artificial chromosome probes, genomic DNA probes, RNA probes, and recombinant nucleic acid probes.

19. The method of claim 12, wherein the first nucleic acid probe is labeled with a fluorophore.

20. The method of claim 12, wherein said complex is detected on the solid support by flow cytometry.

21. The method of claim 12, wherein said complex is detected by detecting a labeled reagent that binds to the detectable label of the first nucleic acid probe.

22. The method of claim 21, wherein said labeled reagent is a labeled antibody that is specific for the detectable label.

23. A method for analyzing nucleic acid from a sample of an individual to determine if the individual has a duplication or deletion associated with a particular chromosomal segment or gene, comprising,

a) forming on a solid support a complex comprising the nucleic acid associated with the particular chromosomal segment or gene which is obtained from the sample, a first nucleic acid probe hybridizing to a first segment of the nucleic acid associated with the particular chromosomal segment or gene, said first nucleic acid probe labeled with a detectable label, and a second nucleic acid probe hybridizing to a second segment of the nucleic acid associated with the particular chromosomal segment or gene, wherein said second nucleic acid probe is anchored to the solid support, and

b) measuring a test value representing the amount of complex formed with nucleic acid associated with the particular chromosomal segment or gene by detecting the amount of detectable label incorporated into the complex, and

c) comparing the amount measured in step b) to a control value obtained for another particular chromosomal segment or gene, wherein an increase in the test value compared to the control value is indicative of a duplication and a decrease in the test value compared to the control value is indicative of a deletion.

24. The method of claim 23, wherein said solid support comprises a first member of a binding pair and said second probe comprises a second member of a binding pair which has binding affinity for said first member of a binding pair, and wherein binding of the first member of the binding pair to the second member of the binding pair anchors the second probe to the support.

25. The method of claim 23, wherein the test value and control value are determined using the same sample.

26. The method of claim 23, wherein a first ratio is obtained using the test value and the control value, and that this ratio is compared to a similar ratio obtained for a test value and a control value from a nucleic acid which has a wildtype sequence for the particular chromosomal segment or gene, and wherein an increase in the first ratio compared to the second ratio is indicative of a duplication and a decrease in the first ratio compared to the second ratio is indicative of a deletion.

27. The method of claim 23, wherein the control value is obtained by forming on a solid support a second complex comprising the nucleic acid associated with a different particular gene, a third nucleic acid probe hybridizing to a first segment of the nucleic acid associated with the different particular gene, said third nucleic acid probe labeled with a detectable label, and a fourth nucleic acid probe hybridizing to a second segment of the nucleic acid associated with the different particular gene, wherein said fourth nucleic acid probe is anchored to the solid support;

and

measuring the amount of second complex formed with nucleic acid associated with the different particular gene by detecting the amount of detectable label incorporated into the complex.

28. The method of claim 27, wherein in the case of said second complex, said solid support comprises a first member of a binding pair and said second probe comprises a second member of a binding pair which has binding affinity for said first member of a binding pair, and wherein binding of the first member of the binding pair to the second member of the binding pair anchors the second probe to the support.

29. The method of claim 27, wherein the test value and control value are determined using the same sample.

30. The method of claim 23, wherein the test value and control value are determined in a single reaction vessel, and wherein said detectable labels of said first nucleic acid probe and said second nucleic acid probe are distinguishable.

31. The method of claim 23, wherein the test value and control value are determined in a separate reaction vessel.

32. The method of claim 28, wherein the binding pair members used to determine the test value are different from the binding pair members used to determine the control value.

33. A method for detecting a chromosomal translocation of a target nucleic acid in a test sample, said method comprising,

forming on a solid support a complex comprising the target nucleic acid, a first nucleic acid probe hybridizing to a region of a first chromosome of the translocation, said first nucleic acid probe labeled with a detectable label, and a second nucleic acid probe hybridizing to a region of a second chromosome of the translocation, wherein said second nucleic acid probe is anchored to the solid support, and

detecting the complex by detecting detectable label incorporated into the complex, wherein said detecting indicates the presence of the chromosomal translocation.

34. The method of claim 33, wherein said solid support comprises a first member of a binding pair and said second probe comprises a second member of a binding pair which has binding affinity for said first member of a binding pair, and wherein binding of the first member of the binding pair to the second member of the binding pair anchors the second probe to the support.

35. The method of claim 33, wherein said wherein said translocation is selected from the group consisting of t(9;

22), t(6;

11), t(11;

16), t(8;

21), t(8;

14), t(4;

14), Inv 16, t(5;

12), t(11;

14), and t(14;

18).

36. The method of claim 33, wherein said first chromosome is chromosome 9 and wherein said second chromosome is chromosome 22.

37. The method of claim 33, wherein said region of the first chromosome comprises the ABL locus and wherein said region of the second chromosome comprises the BCR locus.

38. The method of claim 37, wherein detecting said chromosomal translocation indicates that the individual has chronic myelogenous leukemia (CML).

41. The method of claim 38, wherein said reference sample is taken from a normal individual.

42. The method of claim 38, wherein said amount of complex formed using target nucleic acid from a reference sample is obtained by forming on a solid support a complex comprising the target nucleic acid from said reference sample, a first nucleic acid probe hybridizing to a first segment of the target nucleic acid, said first nucleic acid probe labeled with a detectable label, and a second nucleic acid probe hybridizing to a second segment of the target nucleic acid, wherein said second nucleic acid probe is anchored to the support, and measuring the amount of complex formed by detecting the amount of detectable label incorporated into the complex.

39. A method of determining diagnosis, predicting response to therapy, detecting minimal residual disease or prognosis of a disease in an individual, said method comprising,

a) forming on a solid support a complex comprising the target nucleic acid from a test sample of the individual, a first nucleic acid probe hybridizing to a first segment of the target nucleic acid, said first nucleic acid probe labeled with a detectable label, and a second nucleic acid probe hybridizing to a second segment of the target nucleic acid, wherein said second nucleic acid probe is anchored to the solid support,

b) measuring the amount of complex formed by detecting the amount of detectable label incorporated into the complex;

and

c) comparing the amount of complex formed using target nucleic acid from the test sample to the amount of complex formed using target nucleic acid from a reference sample, wherein a difference in amount of complex formed from the test sample as compared to the reference sample is diagnostic, predicts response to therapy, detects minimal residual disease or is prognostic for said disease.

40. The method of claim 39, wherein said solid support comprises a first member of a binding pair and said second probe comprises a second member of a binding pair which has binding affinity for said first member of a binding pair, and wherein binding of the first member of the binding pair to the second member of the binding pair anchors the second probe to the support.

43. A method of monitoring progression of a disease, said method comprising, obtaining a first sample containing a target nucleic acid from an individual having a disease,

a) forming on a first solid support a first complex comprising a target nucleic acid from said first sample, a second nucleic acid probe hybridizing to a first segment of said target nucleic acid, said first nucleic acid probe labeled with a detectable label, and a second nucleic acid probe hybridizing to a second segment of said target nucleic acid, wherein said second nucleic acid probe is anchored to the first support, and detecting said first complex by measuring the amount of detectable label incorporated into said complex,

b) obtaining a second sample containing a target nucleic acid from said individual having a disease, wherein said second sample is obtained after the first sample;

c) forming on a second solid support a second complex comprising a target nucleic acid from said second sample, a first nucleic acid probe hybridizing to a first segment of said target nucleic acid, said first nucleic acid probe labeled with a detectable label, and a second nucleic acid probe hybridizing to a second segment of said target nucleic acid, wherein said second nucleic acid probe is anchored to the second support, and detecting said complex by measuring the amount of detectable label incorporated into said complex,

d) comparing the amount of said first complex formed from the first sample to the amount of second complex formed from the second sample, wherein a difference in the amount of first complex and second complex is related to the progression of the disease.

44. The method of claim 43, wherein said first or second solid support comprises a first member of a binding pair and said second probe comprises a second member of a binding pair which has binding affinity for said first member of a binding pair, and wherein binding of the first member of the binding pair to the second member of the binding pair anchors the second probe to the support.

45. The method of claim 43, wherein a decrease in the amount of the second complex from the second sample relative to the amount of first complex from the first sample indicates a reduction in the progression of the disease.

46. The method of claim 43, wherein said target nucleic acid in said first and second complex contains a mutation associated with cancer.

47. A method of measuring the tumor burden in an individual suspected of having cancer, said method comprising,

a) forming on a solid support a first complex comprising a first target nucleic acid from a body fluid test sample, a first nucleic acid probe hybridizing to a first segment of said first target nucleic acid, said first nucleic acid probe labeled with a detectable label, and a second nucleic acid probe hybridizing to a second segment of said first target nucleic acid, wherein said second nucleic is anchored to the solid support, and detecting said first complex,

b) comparing the amount measured in step a) to a reference value or set of reference values that relate the amount in step a) to tumor burden.

48. The method of claim 47, further comprising,

a) forming on a second solid support a second complex comprising a second target nucleic acid from said test sample, a third nucleic acid probe hybridizing to a first segment of said second target nucleic acid, wherein said third nucleic acid probe is labeled with a detectable label, and a fourth nucleic acid probe hybridizing to a second segment of said second target nucleic acid, wherein said fourth nucleic acid probe is anchored to the second solid support, and detecting said second complex;

b) determining a ratio of the value obtained from the first target nucleic acid to the value obtained from the second target nucleic acid; and

c) comparing the ratio determined in step b) to a reference ratio or set of reference ratios that relate the ratio in step b) to tumor burden.

49. The method of claim 47, wherein said first or second solid support comprises a first member of a binding pair and said second probe comprises a second member of a binding pair which has binding affinity for said first member of a binding pair, and wherein binding of the first member of the binding pair to the second member of the binding pair anchors the second probe to the support.

50. The method of claim 47 wherein said first and second solid supports are one in the same.